Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity.

MHC class I NK cell education antitumor immunity exosomes extracellular vesicles innate anti-tumor response missing-self response natural killer (NK) cells

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Jan 2021
Historique:
received: 11 12 2020
revised: 09 01 2021
accepted: 12 01 2021
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 21 1 2021
Statut: epublish

Résumé

Natural killer (NK) cells can kill target cells via the recognition of stress molecules and down-regulation of major histocompatibility complex class I (MHC-I). Some NK cells are educated to recognize and kill cells that have lost their MHC-I expression, e.g., tumor or virus-infected cells. A desired property of cancer immunotherapy is, therefore, to activate educated NK cells during anti-tumor responses in vivo. We here analyze NK cell responses to α-galactosylceramide (αGC), a potent activator of invariant NKT (iNKT) cells, or to exosomes loaded with αGC. In mouse strains which express different MHC-I alleles using an extended NK cell flow cytometry panel, we show that αGC induces a biased NK cell proliferation of educated NK cells. Importantly, iNKT cell-induced activation of NK cells selectively increased in vivo missing self-responses, leading to more effective rejection of tumor cells. Exosomes from antigen-presenting cells are attractive anti-cancer therapy tools as they may induce both innate and adaptive immune responses, thereby addressing the hurdle of tumor heterogeneity. Adding αGC to antigen-loaded dendritic-cell-derived exosomes also led to an increase in missing self-responses in addition to boosted T and B cell responses. This study manifests αGC as an attractive adjuvant in cancer immunotherapy, as it increases the functional capacity of educated NK cells and enhances the innate, missing self-based antitumor response.

Identifiants

pubmed: 33467442
pii: cancers13020298
doi: 10.3390/cancers13020298
pmc: PMC7830699
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Immunol. 2013 Mar 15;190(6):2712-9
pubmed: 23418627
Arthritis Res Ther. 2007;9(6):R125
pubmed: 18053164
J Immunol. 2015 Nov 15;195(10):4604-14
pubmed: 26423148
J Clin Invest. 2012 Sep;122(9):3260-70
pubmed: 22863621
Front Immunol. 2018 Aug 28;9:1969
pubmed: 30210505
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Cell Rep. 2020 Jul 28;32(4):107969
pubmed: 32726632
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):11808-11813
pubmed: 30381460
Immunol Rev. 2001 Jun;181:158-69
pubmed: 11513137
Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11
pubmed: 15536127
J Exp Med. 2005 Apr 4;201(7):1145-55
pubmed: 15809355
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
J Transl Med. 2005 Mar 02;3(1):10
pubmed: 15740633
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
J Immunol. 2001 May 15;166(10):6012-8
pubmed: 11342617
J Immunol. 2004 Feb 15;172(4):2126-36
pubmed: 14764678
Eur J Immunol. 2000 Mar;30(3):920-30
pubmed: 10741410
J Exp Med. 2012 Dec 17;209(13):2351-65
pubmed: 23209317
Nature. 2001 Sep 13;413(6852):165-71
pubmed: 11557981
Eur J Immunol. 2015 Jun;45(6):1794-807
pubmed: 25808315
Blood. 2012 Feb 16;119(7):1623-33
pubmed: 22174153
J Hepatol. 2017 Oct;67(4):739-748
pubmed: 28549917
Blood. 2009 Mar 19;113(12):2673-83
pubmed: 19176319
J Immunol. 2014 Apr 15;192(8):3889-97
pubmed: 24634493
J Immunol. 2019 Aug 15;203(4):825-834
pubmed: 31292216
Nature. 2005 Aug 4;436(7051):709-13
pubmed: 16079848
Science. 1997 Nov 28;278(5343):1623-6
pubmed: 9374462
J Immunol. 2013 Jun 15;190(12):6269-76
pubmed: 23656738
J Immunol. 2012 Mar 1;188(5):2218-26
pubmed: 22287714
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
PLoS One. 2008;3(10):e3377
pubmed: 18852879
Cancer Immunol Res. 2016 Feb;4(2):113-23
pubmed: 26589766
Cancer Res. 2013 Jul 1;73(13):3865-76
pubmed: 23658368
Int Immunol. 2007 Apr;19(4):391-400
pubmed: 17307799
Nat Immunol. 2002 Dec;3(12):1163-8
pubmed: 12415264
Blood. 2009 Mar 12;113(11):2434-41
pubmed: 18974374
J Immunol. 2001 Aug 1;167(3):1413-22
pubmed: 11466360
Nature. 1986 Feb 20-26;319(6055):675-8
pubmed: 3951539
Nat Commun. 2017 May 31;8:15627
pubmed: 28561023
Clin Immunol. 2005 Feb;114(2):183-9
pubmed: 15639652
J Immunol. 2002 Apr 15;168(8):3763-70
pubmed: 11937527
J Exp Med. 2010 May 10;207(5):943-52
pubmed: 20439539
Biol Blood Marrow Transplant. 2017 Mar;23(3):398-404
pubmed: 27894857
Blood. 2013 Apr 4;121(14):2678-88
pubmed: 23325834
Oncoimmunology. 2015 Aug 12;5(4):e1071008
pubmed: 27141373
J Immunol. 2009 Aug 15;183(4):2522-8
pubmed: 19635904
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9464-9
pubmed: 12867593
J Immunol. 2014 Feb 15;192(4):1954-61
pubmed: 24415778
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10332-6
pubmed: 1946452
Blood. 2012 Dec 6;120(24):4751-60
pubmed: 22983442
J Immunol. 2001 Jun 1;166(11):6578-84
pubmed: 11359810
Cancer Lett. 2017 Dec 28;411:182-190
pubmed: 28947140
Proc Natl Acad Sci U S A. 2019 Dec 16;:
pubmed: 31843910
Nat Rev Cancer. 2002 Nov;2(11):850-61
pubmed: 12415255
J Leukoc Biol. 2016 Oct;100(4):781-789
pubmed: 27034402
Nat Immunol. 2010 Apr;11(4):321-7
pubmed: 20190757
J Immunol. 1999 Nov 1;163(9):4647-50
pubmed: 10528160
Immunity. 2006 Aug;25(2):331-42
pubmed: 16901727
J Allergy Clin Immunol. 2019 Jan;143(1):346-358.e6
pubmed: 30096390
J Exp Med. 1999 Apr 5;189(7):1121-8
pubmed: 10190903
Immunity. 2000 Jun;12(6):721-7
pubmed: 10894171
Nat Immunol. 2010 Apr;11(4):313-20
pubmed: 20190758
Cancers (Basel). 2020 Jan 07;12(1):
pubmed: 31936065
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
PLoS Pathog. 2016 Feb 29;12(2):e1005446
pubmed: 26928844
Cancer Res. 2014 Jul 15;74(14):3684-94
pubmed: 24802191
Int Immunol. 2000 Dec;12(12):1669-75
pubmed: 11099306
J Immunol. 2007 Apr 15;178(8):4764-70
pubmed: 17404256
Trends Immunol. 2009 Apr;30(4):143-9
pubmed: 19282243
Eur J Immunol. 2020 Apr;50(4):494-504
pubmed: 31834938
PLoS One. 2009;4(3):e4942
pubmed: 19319200
Science. 2002 May 17;296(5571):1323-6
pubmed: 11950999
Nat Rev Immunol. 2005 Feb;5(2):112-24
pubmed: 15688039
Blood. 2005 Jan 15;105(2):721-7
pubmed: 15367431
Blood. 2009 May 28;113(22):5488-96
pubmed: 19234143
Sci Rep. 2016 Dec 01;6:37996
pubmed: 27905484
Nat Immunol. 2002 Dec;3(12):1156-62
pubmed: 12426563
J Exp Med. 2005 Jun 20;201(12):1973-85
pubmed: 15967825
Immunol Rev. 1997 Feb;155:11-28
pubmed: 9059879
Eur J Immunol. 2009 Sep;39(9):2548-55
pubmed: 19701893
Sci Rep. 2017 Dec 6;7(1):17095
pubmed: 29213052
PLoS One. 2019 Mar 7;14(3):e0203247
pubmed: 30845234
Science. 1997 Nov 28;278(5343):1626-9
pubmed: 9374463
Immunity. 2003 Oct;19(4):561-9
pubmed: 14563320
Front Pharmacol. 2019 Oct 11;10:1184
pubmed: 31680963
J Exp Med. 2004 Jun 21;199(12):1607-18
pubmed: 15197224
Eur J Immunol. 1975 Feb;5(2):112-7
pubmed: 1234049
Blood. 2005 Jun 1;105(11):4416-23
pubmed: 15728129
J Exp Med. 2001 Mar 19;193(6):661-70
pubmed: 11257133
J Clin Invest. 2005 Sep;115(9):2572-83
pubmed: 16138194

Auteurs

Arnika K Wagner (AK)

Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.
Center for Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden.

Ulf Gehrmann (U)

Division of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.

Stefanie Hiltbrunner (S)

Division of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.

Valentina Carannante (V)

Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.

Thuy T Luu (TT)

Center for Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden.

Tanja I Näslund (TI)

Division of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.

Hanna Brauner (H)

Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Dermato-Venerology Clinic, Karolinska University Hospital, SE-17164 Stockholm, Sweden.

Nadir Kadri (N)

Center for Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden.
Science for Life Laboratory, Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.

Klas Kärre (K)

Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.

Susanne Gabrielsson (S)

Division of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.

Classifications MeSH